Kidney and Hypertension Unit, Joslin Diabetes Center, Boston, Massachusetts, USA,
Harvard Medical School, Boston, Massachusetts, USA,
Am J Nephrol. 2021;52(9):745-752. doi: 10.1159/000518652. Epub 2021 Sep 15.
Inflammation is important in the pathogenesis of atherosclerosis. Elevated interleukin-6 (IL-6) is associated with cardiovascular events and also predicts mortality in individuals with CKD. Our goal was to determine the association between IL-6, FGF23, and high-sensitivity C-reactive protein (hsCRP) on coronary artery calcification (CAC) progression and mortality in incident dialysis patients without prior coronary events.
A prospective cohort of incident adult dialysis participants had CAC measured by ECG-triggered multislice CT scans at baseline and at least 12 months later. Lipids, mineral metabolism markers, FGF23, and inflammatory markers, such as IL-6 and hsCRP, were measured at the baseline visit.
Participants in the high IL-6 tertile had the highest baseline CAC score (133.25 [10.35-466.15]) compared to the low (0.25 [0-212.2]) and intermediate (29.55 [0-182.85]) tertiles. Almost half of the participants with high IL-6 (15 of 32 [46.9%]) experienced progression of CAC compared to participants with low (8 of 32 [25%]) and intermediate (9 of 32 [28.1%]) (p = 0.05) IL-6 levels. Each log increase in IL-6 was associated with increase in death (hazard ratio 2.2, 95% CI: 1.2-3.8; p = 0.01). After adjusting for smoking, age, gender, race, diabetes, phosphate, and baseline calcium score, IL-6 (log) was associated with 2.2 times (95% CI: 1.1-4.6; p = 0.03) increase in death.
IL-6 is associated with progression of CAC and mortality in incident dialysis patients.
炎症在动脉粥样硬化的发病机制中起重要作用。白细胞介素-6(IL-6)升高与心血管事件相关,也可预测 CKD 患者的死亡率。我们的目标是确定 IL-6、成纤维细胞生长因子 23(FGF23)和高敏 C 反应蛋白(hsCRP)与无既往冠状动脉事件的新透析患者冠状动脉钙化(CAC)进展和死亡率之间的关系。
前瞻性队列研究纳入了新发生的成年透析患者,他们在基线时和至少 12 个月后通过心电图触发的多层 CT 扫描测量 CAC。脂质、矿物质代谢标志物、FGF23 和炎症标志物,如 IL-6 和 hsCRP,在基线时进行测量。
与低(0.25 [0-212.2])和中(29.55 [0-182.85])三分位组相比,IL-6 三分位组的患者基线 CAC 评分最高(133.25 [10.35-466.15])。与低(8 例 [25%])和中(9 例 [28.1%])IL-6 水平的患者相比,几乎一半(15 例 [46.9%])IL-6 较高的患者发生 CAC 进展(p = 0.05)。IL-6 每增加一个对数单位,死亡风险增加(危险比 2.2,95%CI:1.2-3.8;p = 0.01)。在校正吸烟、年龄、性别、种族、糖尿病、磷酸盐和基线钙评分后,IL-6(对数)与死亡风险增加 2.2 倍(95%CI:1.1-4.6;p = 0.03)相关。
IL-6 与新透析患者 CAC 进展和死亡率相关。